Get the Stockscreener App
2.36
0.00%
0.010
Galectin Therapeutics Inc stock is traded at $2.36, with a volume of 88,015.
It is up +0.00% in the last 24 hours and up +2.62% over the past month.
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.
See More
Previous Close:
$2.35
Open:
$2.35
24h Volume:
88,015
Relative Volume:
0.25
Market Cap:
$155.42M
Revenue:
-
Net Income/Loss:
$-30.84M
P/E Ratio:
-4.867
EPS:
-0.4849
Net Cash Flow:
$-23.88M
1W Performance:
-8.56%
1M Performance:
+2.62%
6M Performance:
-62.93%
1Y Performance:
+83.59%
1-Day Range:
$2.345
$2.45
1-Week Range:
$2.30
$2.70
52-Week Range:
$1.27
$7.13
Galectin Therapeutics Inc Stock (GALT) Company Profile
Name
Galectin Therapeutics Inc
Sector
Industry
Phone
678-620-3186
Address
4960 PEACHTREE INDUSTRIAL BOULEVARD, NORCROSS, GA
Compare GALT vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GALT
Galectin Therapeutics Inc
|
2.36 | 154.76M | 0 | -30.84M | -23.88M | -0.4849 |
VRTX
Vertex Pharmaceuticals Inc
|
444.87 | 108.72B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
627.31 | 64.89B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
847.12 | 50.57B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
302.78 | 39.06B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
155.47 | 33.16B | 742.00K | -1.37B | -1.07B | -7.0731 |
Galectin Therapeutics Inc Stock (GALT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-17-25 | Resumed | H.C. Wainwright | Buy |
| Aug-13-20 | Reiterated | H.C. Wainwright | Buy |
| Feb-13-19 | Initiated | B. Riley FBR | Buy |
| Dec-07-17 | Reiterated | H.C. Wainwright | Buy |
| Nov-28-17 | Reiterated | H.C. Wainwright | Buy |
| Oct-19-17 | Initiated | ROTH Capital | Buy |
| Mar-30-17 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Oct-03-16 | Downgrade | FBR & Co. | Outperform → Mkt Perform |
| Sep-29-16 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Sep-28-16 | Downgrade | ROTH Capital | Buy → Sell |
| Mar-28-16 | Resumed | H.C. Wainwright | Buy |
| Sep-21-15 | Initiated | H.C. Wainwright | Buy |
| Aug-01-14 | Downgrade | Aegis Capital | Buy → Hold |
| Jul-30-14 | Reiterated | MLV & Co | Buy |
| Jul-29-14 | Reiterated | MLV & Co | Buy |
| Apr-02-14 | Reiterated | MLV & Co | Buy |
| Feb-10-14 | Reiterated | Aegis Capital | Buy |
| Jan-09-14 | Reiterated | Aegis Capital | Buy |
| Dec-03-13 | Initiated | MLV & Co | Buy |
| Aug-19-13 | Reiterated | Aegis Capital | Buy |
View All
Galectin Therapeutics Inc Stock (GALT) Latest News
GALT Stock Price, Quote & Chart | GALECTIN THERAPEUTICS INC (NASDAQ:GALT) - ChartMill
Galectin Therapeutics CMO Jamil Khurram sells $1,761 in GALT stock By Investing.com - Investing.com India
Galectin Therapeutics CMO Jamil Khurram sells $1,761 in GALT stock - Investing.com
Galectin Therapeutics (GALT) CMO sells 568 shares after option exercise - Stock Titan
Galectin Therapeutics (GALT) Unveils New Insights from NAVIGATE Trial at EASL 2026 - GuruFocus
GALT Q1 2026 Earnings: EPS Misses Estimates as Clinical Development ContinuesPre-Earnings Setup - thelegaladvocate.com
Galectin Therapeutics Presents New EASL 2026 Oral and Poster Analyses Demonstrating Belapectin’s Potential to Modify Disease Progression in Advanced MASH Cirrhosis - The Manila Times
Galectin Therapeutics (GALT) Holds Near $2.50 After Modest DeclineATR Stop - Newser
GALT Q1 2026 Earnings: Narrowed Loss Amid Clinical Progress, Stock RallyEPS Estimate Trend - newsline.com
Galectin Therapeutics (GALT) Q1 2026 Results Miss Estimates — EPS $-0.08 vs $-0.06Special Dividend Alert - Newser
Number of shareholders of Galectin Therapeutics Inc. – NASDAQ:GALT - TradingView
TradingKey - TradingKey
Galectin Therapeutics 1Q Research and Development Expenses $2.2M >GALT - Moomoo
Galectin Therapeutics Q1 2026 Financial Report: Earnings, Balance Sheet, and Key Disclosures - Minichart
Galectin Therapeutics Releases Q1 2026 Financial Results - AlphaStreet
Is Galectin Therapeutics (GALT) Fairly Valued After Q1 2026 Earn - GuruFocus
Correct: Galectin Therapeutics 1Q Loss/Shr 8c >GALT - Moomoo
Galectin Therapeutics Reports Q1 2026 Financial Results and Advances Belapectin for MASH Cirrhosis with Positive NAVIGATE Trial Data 123 - Minichart
Galectin Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Galectin Therapeutics Reports March 31, 2026 Financial Results and Provides Business Update - The Manila Times
Belapectin reduces liver stiffness in high-risk MASH cirrhosis trial - Stock Titan
Galectin Therapeutics reports Q1 2026 net loss of $5.1M, cash $14.1M; updates belapectin program - TradingView
Galectin Therapeutics 1Q 2026: Financials Not Reported — 10-Q Summary - TradingView
Galectin Therapeutics (NASDAQ: GALT) trims Q1 2026 loss as R&D falls - Stock Titan
Galectin Therapeutics (NASDAQ: GALT) narrows Q1 2026 loss but leans on large convertible debt - Stock Titan
Galectin Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Will Galectin's New MASH Cirrhosis Data Renew Stock Momentum? - RTTNews
Galectin Therapeutics (GALT) Highlights Promising Phase 2b Trial Results - GuruFocus
Galectin Therapeutics Inc expected to post a loss of 6 cents a shareEarnings Preview - TradingView
Galectin Therapeutics announces publication of Navigate phase 2b trial results for belapectin in the Journal of Hepatology - marketscreener.com
Galectin publishes phase 2b trial results in Hepatology - Investing.com
Galectin Therapeutics Announces Publication Of Navigate Phase 2B Trial Results For Belapectin In The Journal Of Hepatology - TradingView
Galectin publishes phase 2b trial results in Hepatology By Investing.com - Investing.com Australia
Galectin Therapeutics Announces Publication of NAVIGATE Phase 2b Trial Results for Belapectin in the Journal of Hepatology - Yahoo Finance
Why Galectin Therapeutics (GALT) guidance matters more than actual results | Q4 2025: Better Than ExpectedBuy Rating - newser.com
Galectin Therapeutics to Present New Data on the Treatment of Fatty Liver Disease and Fibrosis at AA - Yahoo
Galectin Therapeutics, Inc. Investigated by the Portnoy Law Firm - GlobeNewswire
Galectin Therapeutics (GALT) upgraded to buy: What does it mean for the stock? - MSN
GALT Price Today: Galectin Therapeutics Inc. Stock Price, Quote & Chart | MEXC - MEXC Exchange
What are the key catalysts for Galectin Therapeutics (GALT) stock (Drifts Higher) 2026-04-23Revenue Growth Stocks - The Legal Advocate
GALT (Galectin Therapeutics Inc.) Q4 2025 narrower than expected loss drives 8.41 percent share gain amid positive investor sentiment.Earnings Per Share - UBND thành phố Hải Phòng
GALT (Galectin Therapeutics Inc.) posts narrower Q4 2025 loss than estimates, shares gain 3.64 percent on upbeat investor reaction.Expert Momentum Signals - UBND thành phố Hải Phòng
Is institutional money buying Galectin Therapeutics (GALT) stock (Smart Money Exits) 2026-04-20Open Stock Signal Network - UBND thành phố Hải Phòng
Galectin Therapeutics Inc Stock (GALT) Financials Data
Revenue
Net Income
Cash Flow
EPS
Galectin Therapeutics Inc Stock (GALT) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Jamil Khurram | Chief Medical Officer |
May 26 '26 |
Sale |
3.10 |
568 |
1,761 |
0 |
| ELDRED KARY | Director |
Feb 06 '26 |
Buy |
2.70 |
300 |
810 |
65,682 |
| LEWIS JOEL | President and CEO |
Jan 02 '26 |
Option Exercise |
0.00 |
84,000 |
0 |
916,592 |
| LEWIS JOEL | President and CEO |
Jan 06 '26 |
Sale |
3.58 |
37,698 |
134,853 |
832,592 |
| LEWIS JOEL | President and CEO |
Jan 05 '26 |
Sale |
3.91 |
27,731 |
108,342 |
870,290 |
| LEWIS JOEL | President and CEO |
Jan 02 '26 |
Sale |
4.20 |
18,571 |
77,939 |
898,021 |
| CALLICUTT JACK W | Chief Financial Officer |
Jan 02 '26 |
Option Exercise |
0.00 |
60,000 |
0 |
67,614 |
| CALLICUTT JACK W | Chief Financial Officer |
Jan 05 '26 |
Sale |
3.90 |
25,732 |
100,298 |
27,968 |
| CALLICUTT JACK W | Chief Financial Officer |
Jan 06 '26 |
Sale |
3.67 |
20,354 |
74,695 |
7,614 |
| CALLICUTT JACK W | Chief Financial Officer |
Jan 02 '26 |
Sale |
4.20 |
13,914 |
58,394 |
53,700 |
0.41%
0.21%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):